Desmoid Tumors Epidemiology Forecast 2025-2034

Desmoid tumors are rare, primarily affecting adults aged 20-44, with higher prevalence in females; early diagnosis and awareness of sporadic and FAP-associated cases are crucial for effective management. The desmoid tumors epidemiology forecast by Expert Market Research indicates that approximately 85-90% of desmoid tumors occur sporadically due to somatic CTNNB1 (β-catenin) mutations, while 5-10% are associated with familial adenomatous polyposis (FAP) or Gardner syndrome, linked to APC gene mutations.

Desmoid Tumors Epidemiology Forecast Report Coverage

Expert Market Research's “Desmoid Tumors Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of desmoid tumors. It projects the future incidence and prevalence rates of desmoid tumors cases across various populations. The study covers age, gender, and type as major determinants of the desmoid tumors population. The report highlights patterns in the prevalence of desmoid tumors over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on desmoid tumors epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Desmoid Tumors Understanding: Disease Overview

Desmoid tumors, also known as aggressive fibromatosis, are rare, non-cancerous growths originating from connective tissue, particularly fibroblasts. They can develop in various body parts, including the abdominal wall, limbs, and chest. While benign, these tumors can be locally invasive, leading to pain, functional impairment, and potential complications due to their proximity to vital structures. The exact cause remains unclear, but genetic mutations, especially in the APC or CTNNB1 genes, and associations with conditions like familial adenomatous polyposis (FAP) are noted.

Desmoid Tumors Epidemiology Perspective

The desmoid tumors epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the desmoid tumors epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for desmoid tumors and their trends. The desmoid tumors detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The estimated annual incidence is approximately 2-5 cases per 1 million individuals, accounting for < 0.03% of all neoplasms and about 3% of all soft tissue tumors.
• Most patients are diagnosed between the ages of 15 and 60 years, with a peak incidence between 30 and 40 years.
• Desmoid tumors are more common in females, with a median age of diagnosis of 38 years. Tumor development is sometimes associated with hormonal influences (such as pregnancy or estrogen exposure).
• Approximately 85% to 90% of desmoid tumors are sporadic, while about 10% to 15% are associated with mutations in the APC gene, often in patients with a family history of colon cancer.

Country-wise Desmoid Tumors Epidemiology Segment

The desmoid tumors epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, desmoid tumors, also known as desmoid-type fibromatosis, affect approximately 1,000 to 1,650 individuals annually. These rare, non-metastatic tumors predominantly occur in adults aged 20-44 years and show a higher prevalence in females, with a female-to-male ratio of 2-3:1. While most cases are sporadic, about 10-12% are associated with familial adenomatous polyposis (FAP) due to APC gene mutations. Early diagnosis and awareness of risk factors are essential for appropriate management and improved clinical outcomes in the United States population.

Desmoid Tumors: Treatment Overview

Management of desmoid tumors is tailored based on tumor size, location, symptoms, and growth behavior. Asymptomatic or slow-growing tumors may be monitored through active surveillance. For symptomatic or rapidly progressing cases, treatment options include surgery, radiation therapy, and systemic therapies. The FDA-approved medication, Ogsiveo (nirogacestat), has shown promise in clinical trials for reducing tumor size and improving quality of life. Other systemic treatments under investigation include γ-secretase inhibitors and tyrosine kinase inhibitors.

Key Questions Answered

• What are the key findings of desmoid tumors epidemiology in the 8 major markets?
• What will be the total number of patients with desmoid tumors across the 8 major markets during the forecast period?
• What was the country-wise desmoid tumors epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of desmoid tumors during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of desmoid tumors during the forecast period of 2025-2034?
• What are the currently available treatments for desmoid tumors?
• What are the disease risks, signs, symptoms, and unmet needs of desmoid tumors?

Scope of the Desmoid Tumors Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of desmoid tumors based on several factors.
• Desmoid Tumors Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The desmoid tumors report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.